Chorionic Gonadotropin Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: The Chorionic Gonadotropin Shortage in 2026

The Chorionic Gonadotropin (HCG) supply disruption is now in its sixth year, and providers across reproductive endocrinology, urology, endocrinology, and primary care continue to navigate its effects on patient care. This article provides an evidence-based update on the shortage's current status, its prescribing implications, cost considerations, and practical tools to help your patients access treatment.

Whether you're managing IVF trigger protocols, TRT adjunct therapy, or pediatric cryptorchidism, this briefing covers what you need to know to adapt your practice in 2026.

Timeline: How We Got Here

Understanding the history of this shortage helps contextualize the current situation and set realistic expectations for resolution.

March 2020: Biologic Reclassification

The Biologics Price Competition and Innovation Act (BPCIA), enacted in 2009, took effect on March 23, 2020, reclassifying HCG from a drug to a biologic product. This transition meant that compounding pharmacies — previously a major supply source, particularly for men's health clinics — could no longer produce HCG without a biologics license under Section 351 of the Public Health Service Act.

The immediate impact was significant. Compounding pharmacies had been supplying an estimated large share of HCG used in TRT adjunct protocols. That supply effectively vanished overnight.

2020–2022: Initial Supply Disruption

Demand shifted entirely to FDA-approved manufacturers: Organon (Pregnyl), Ferring Pharmaceuticals (Novarel), EMD Serono (Ovidrel), and a limited number of generic producers. These manufacturers could not immediately scale to meet the demand surge. Backorders became common.

2022–2023: FDA Enforcement

The FDA issued enforcement actions against compounding pharmacies still producing HCG without proper authorization. This further constricted remaining alternative supply channels and reinforced the dependence on FDA-approved products.

2024–2025: Intermittent Availability

Supply stabilized somewhat as manufacturers adjusted production capacity, but intermittent shortages persisted. The drug remains listed on the ASHP drug shortage database. Regional availability continues to vary significantly.

2026: Current State

Chorionic Gonadotropin availability remains inconsistent but not absent. FDA-approved products are being manufactured, but supply-demand equilibrium has not been fully restored. Specialty pharmacies tend to have the most reliable access.

Prescribing Implications

The shortage affects clinical decision-making across multiple specialties. Here are the key considerations:

Reproductive Endocrinology

• Trigger shot protocols: Consider incorporating Ovidrel (Choriogonadotropin Alfa, 250 mcg SubQ) as a standard alternative. Its recombinant manufacturing may offer more predictable supply.
• GnRH agonist triggers: For patients in antagonist protocols, Leuprolide Acetate (Lupron) 1–2 mg SubQ can serve as an effective trigger with reduced OHSS risk. This approach has gained broader adoption during the shortage.
• Dual triggers: Some protocols combine a reduced HCG dose (1,000–2,500 units) with Lupron to balance efficacy and OHSS prevention.

Urology and Men's Health

• TRT adjunct therapy: HCG (typically 500–2,500 units 2–3 times weekly) to maintain testicular volume and intratesticular testosterone. When unavailable, Clomiphene Citrate (25–50 mg daily or every other day) and Enclomiphene are off-label alternatives that stimulate endogenous gonadotropin release.
• Fertility preservation during TRT: If HCG is unavailable and fertility preservation is a priority, consider pausing or reducing exogenous testosterone and using Clomiphene or hMG (Menopur) to maintain spermatogenesis.

Pediatric Endocrinology

• Cryptorchidism: HCG remains first-line pharmacological therapy (4,000 units IM three times weekly for three weeks, or other established protocols). When unavailable, surgical orchiopexy should be discussed as the definitive treatment. GnRH analogs have limited evidence and are not widely used in the U.S.

Current Availability Picture

Based on pharmacy and distributor data in early 2026:

• Pregnyl 10,000 units: Available intermittently through major distributors; better availability at specialty pharmacies
• Novarel 10,000 units: Similar intermittent pattern
• Generic HCG 10,000 units: Variable; some generic manufacturers have maintained more consistent output
• Ovidrel 250 mcg: Generally more available than urinary-derived products

Availability varies significantly by region, wholesaler, and pharmacy type. Real-time pharmacy inventory tools like Medfinder for Providers can help your staff identify which pharmacies currently have stock before sending prescriptions.

Cost and Access Considerations

Cost barriers compound the availability problem. Many patients, particularly those using HCG for fertility or off-label TRT support, face significant out-of-pocket expenses:

• Generic HCG: $80–$200 per 10,000-unit vial
• Pregnyl/Novarel (brand): $100–$250 per vial
• Ovidrel: $200–$400+ per prefilled syringe
• Average retail without insurance: ~$465 per vial

Insurance coverage varies by plan and indication. Fertility-related uses often require prior authorization, and some payors require step therapy. Patients should be counseled to:

• Use prescription discount cards (GoodRx, SingleCare, RxSaver) to reduce cash prices by 30–60%
• Check with RESOLVE, NeedyMeds, and the Cade Foundation for financial assistance
• Ask about generic alternatives, which can be significantly cheaper than brand-name products

Tools and Resources for Your Practice

Several resources can help streamline your management of the HCG shortage:

Real-Time Pharmacy Inventory

Medfinder for Providers allows your team to check which pharmacies near your patients have Chorionic Gonadotropin in stock before prescribing. This reduces prescription rejections and patient callbacks.

ASHP Drug Shortage Database

The ASHP Drug Shortages Resource Center (ashp.org) provides official shortage tracking for Chorionic Gonadotropin (Human) for Injection, including estimated resolution timelines and manufacturer updates.

Patient Education Resources

Direct your patients to evidence-based resources that can help them navigate the shortage independently:

• Patient shortage update
• How to find Chorionic Gonadotropin in stock
• How to save money on Chorionic Gonadotropin

Looking Ahead

Several factors suggest gradual improvement in HCG availability:

• Manufacturer capacity expansion: Both Organon and Ferring have reportedly increased production capacity since 2020
• Alternative protocol adoption: Broader use of Lupron triggers and Clomiphene reduces aggregate HCG demand
• Market signals: Sustained high pricing incentivizes additional generic manufacturers to enter the market

However, a return to pre-2020 abundance is unlikely. The compounding pharmacy supply channel is permanently reduced, and the biological nature of HCG manufacturing limits rapid scaling.

Final Thoughts

The Chorionic Gonadotropin shortage requires adaptive prescribing, proactive pharmacy coordination, and clear patient communication. Key takeaways for your practice:

1. Maintain familiarity with alternative protocols (Ovidrel, Lupron triggers, Clomiphene) so you can pivot quickly when supply is unavailable
2. Use real-time inventory tools like Medfinder for Providers to minimize prescription fill failures
3. Educate patients proactively about the shortage, cost-saving strategies, and alternative options
4. Plan ahead for time-sensitive protocols — coordinate with specialty pharmacies well in advance of treatment cycles
5. Monitor ASHP and FDA for supply updates and potential new market entrants

For a patient-facing version of this information, see our patient shortage update. For a practical workflow guide, read how to help your patients find Chorionic Gonadotropin in stock.